HUP9900849A3 - Methods for preparing pharmaceutical compositions for minimizing bone loss effect of danazol - Google Patents
Methods for preparing pharmaceutical compositions for minimizing bone loss effect of danazolInfo
- Publication number
- HUP9900849A3 HUP9900849A3 HU9900849A HUP9900849A HUP9900849A3 HU P9900849 A3 HUP9900849 A3 HU P9900849A3 HU 9900849 A HU9900849 A HU 9900849A HU P9900849 A HUP9900849 A HU P9900849A HU P9900849 A3 HUP9900849 A3 HU P9900849A3
- Authority
- HU
- Hungary
- Prior art keywords
- danazol
- methods
- pharmaceutical compositions
- bone loss
- preparing pharmaceutical
- Prior art date
Links
- 206010065687 Bone loss Diseases 0.000 title 1
- POZRVZJJTULAOH-LHZXLZLDSA-N danazol Chemical compound C1[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=CC2=C1C=NO2 POZRVZJJTULAOH-LHZXLZLDSA-N 0.000 title 1
- 229960000766 danazol Drugs 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Nutrition Science (AREA)
- Rheumatology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Control Of Motors That Do Not Use Commutators (AREA)
- Surface Acoustic Wave Elements And Circuit Networks Thereof (AREA)
- Glass Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/467,475 US5599822A (en) | 1995-06-06 | 1995-06-06 | Methods for minimizing bone loss |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP9900849A2 HUP9900849A2 (hu) | 1999-09-28 |
| HUP9900849A3 true HUP9900849A3 (en) | 1999-11-29 |
Family
ID=23855853
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU9900849A HUP9900849A3 (en) | 1995-06-06 | 1996-06-05 | Methods for preparing pharmaceutical compositions for minimizing bone loss effect of danazol |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US5599822A (hu) |
| EP (1) | EP0747054B1 (hu) |
| JP (1) | JPH11507051A (hu) |
| KR (1) | KR19990022498A (hu) |
| CN (1) | CN1192145A (hu) |
| AU (1) | AU696209B2 (hu) |
| BR (1) | BR9608389A (hu) |
| CA (1) | CA2223055A1 (hu) |
| CO (1) | CO4700446A1 (hu) |
| CZ (1) | CZ382997A3 (hu) |
| DE (1) | DE69623074T2 (hu) |
| EA (1) | EA000763B1 (hu) |
| ES (1) | ES2181849T3 (hu) |
| HU (1) | HUP9900849A3 (hu) |
| IL (1) | IL118590A (hu) |
| NO (1) | NO975581L (hu) |
| PL (1) | PL323935A1 (hu) |
| TR (1) | TR199701507T1 (hu) |
| TW (1) | TW372969B (hu) |
| WO (1) | WO1996039138A1 (hu) |
| YU (1) | YU34396A (hu) |
| ZA (1) | ZA964778B (hu) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9702401D0 (sv) | 1997-06-19 | 1997-06-19 | Astra Ab | Pharmaceutical use |
| US6096764A (en) * | 1997-08-21 | 2000-08-01 | Eli Lilly And Company | Methods for inhibiting detrimental side-effects due to GnRH of GnRH agonist administration |
| DE19825591A1 (de) * | 1998-06-09 | 1999-12-23 | Jenapharm Gmbh | Pharmazeutische Kombinationen zum Ausgleich eines Testosteron-Defizits beim Mann mit gleichzeitigem Schutz der Prostata |
| WO2001035946A2 (en) * | 1999-11-15 | 2001-05-25 | New Millennium Pharmaceutical Research, Inc. | Intranasal administration of raloxifene and tamoxifen |
| EP1113007A1 (en) | 1999-12-24 | 2001-07-04 | Pfizer Inc. | Tetrahydroisoquinoline compounds as estrogen agonists/antagonists |
| US20050124537A1 (en) * | 2000-04-27 | 2005-06-09 | Amgen Inc. | Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein |
| US6756480B2 (en) | 2000-04-27 | 2004-06-29 | Amgen Inc. | Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein |
| EP1180364A1 (en) * | 2000-08-15 | 2002-02-20 | Octagene GmbH | Steroid hormones as transfer agents |
| PL374845A1 (en) | 2002-07-22 | 2005-11-14 | Eli Lilly And Company | Selective estrogen receptor modulators containing a phenylsulfonyl group |
| JP2007537274A (ja) | 2004-05-10 | 2007-12-20 | ナステック ファーマスーティカル カンパニー インク． | 副甲状腺ホルモンの粘膜送達を増強するための組成物及び方法 |
| EP1744683B1 (en) * | 2004-05-13 | 2016-03-16 | Alza Corporation | Apparatus and method for transdermal delivery of parathyroid hormone agents |
| WO2007044375A2 (en) * | 2005-10-06 | 2007-04-19 | Nastech Pharmaceutical Company Inc. | Pth formulations and methods of use |
| AU2006299887A1 (en) * | 2005-10-06 | 2007-04-19 | Nastech Pharmaceutical Company Inc. | PTH formulations and methods of use |
| CN110809473A (zh) * | 2017-06-01 | 2020-02-18 | 延世大学校产学协力团 | 用于预防或治疗骨相关疾病的药物组合物 |
| CN108785264A (zh) * | 2018-07-03 | 2018-11-13 | 威海贯标信息科技有限公司 | 一种达那唑片剂组合物 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3135743A (en) * | 1960-06-29 | 1964-06-02 | Sterling Drug Inc | Steroido[2. 3-d]isoxazoles and preparation thereof |
| US4133814A (en) * | 1975-10-28 | 1979-01-09 | Eli Lilly And Company | 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents |
| US4418068A (en) * | 1981-04-03 | 1983-11-29 | Eli Lilly And Company | Antiestrogenic and antiandrugenic benzothiophenes |
| US4380635A (en) * | 1981-04-03 | 1983-04-19 | Eli Lilly And Company | Synthesis of acylated benzothiophenes |
| US5075321A (en) * | 1987-03-24 | 1991-12-24 | University Of Pennsylvania | Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes |
| TW366342B (en) * | 1992-07-28 | 1999-08-11 | Lilly Co Eli | The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss |
-
1995
- 1995-06-06 US US08/467,475 patent/US5599822A/en not_active Expired - Fee Related
-
1996
- 1996-06-05 WO PCT/US1996/008875 patent/WO1996039138A1/en not_active Application Discontinuation
- 1996-06-05 KR KR1019970708979A patent/KR19990022498A/ko not_active Application Discontinuation
- 1996-06-05 EA EA199800013A patent/EA000763B1/ru not_active IP Right Cessation
- 1996-06-05 CO CO96029177A patent/CO4700446A1/es unknown
- 1996-06-05 HU HU9900849A patent/HUP9900849A3/hu unknown
- 1996-06-05 CN CN96195975A patent/CN1192145A/zh active Pending
- 1996-06-05 CZ CZ973829A patent/CZ382997A3/cs unknown
- 1996-06-05 JP JP9501343A patent/JPH11507051A/ja active Pending
- 1996-06-05 YU YU34396A patent/YU34396A/sh unknown
- 1996-06-05 CA CA002223055A patent/CA2223055A1/en not_active Abandoned
- 1996-06-05 TR TR97/01507T patent/TR199701507T1/xx unknown
- 1996-06-05 AU AU60430/96A patent/AU696209B2/en not_active Ceased
- 1996-06-05 PL PL96323935A patent/PL323935A1/xx unknown
- 1996-06-05 BR BR9608389A patent/BR9608389A/pt unknown
- 1996-06-06 DE DE69623074T patent/DE69623074T2/de not_active Expired - Fee Related
- 1996-06-06 ES ES96304180T patent/ES2181849T3/es not_active Expired - Lifetime
- 1996-06-06 IL IL11859096A patent/IL118590A/xx not_active IP Right Cessation
- 1996-06-06 EP EP96304180A patent/EP0747054B1/en not_active Expired - Lifetime
- 1996-06-06 ZA ZA9604778A patent/ZA964778B/xx unknown
- 1996-06-06 TW TW085106756A patent/TW372969B/zh active
-
1997
- 1997-12-03 NO NO975581A patent/NO975581L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JPH11507051A (ja) | 1999-06-22 |
| BR9608389A (pt) | 1999-05-04 |
| NO975581D0 (no) | 1997-12-03 |
| HUP9900849A2 (hu) | 1999-09-28 |
| EA000763B1 (ru) | 2000-04-24 |
| KR19990022498A (ko) | 1999-03-25 |
| ES2181849T3 (es) | 2003-03-01 |
| CA2223055A1 (en) | 1996-12-12 |
| CN1192145A (zh) | 1998-09-02 |
| NO975581L (no) | 1997-12-03 |
| AU6043096A (en) | 1996-12-24 |
| PL323935A1 (en) | 1998-04-27 |
| US5599822A (en) | 1997-02-04 |
| YU34396A (sh) | 1999-07-28 |
| TW372969B (en) | 1999-11-01 |
| CZ382997A3 (cs) | 1998-09-16 |
| DE69623074T2 (de) | 2003-05-08 |
| EP0747054B1 (en) | 2002-08-21 |
| TR199701507T1 (xx) | 1998-02-21 |
| EP0747054A3 (en) | 1997-03-05 |
| IL118590A (en) | 1999-10-28 |
| DE69623074D1 (de) | 2002-09-26 |
| EP0747054A2 (en) | 1996-12-11 |
| AU696209B2 (en) | 1998-09-03 |
| IL118590A0 (en) | 1996-10-16 |
| WO1996039138A1 (en) | 1996-12-12 |
| EA199800013A1 (ru) | 1998-06-25 |
| ZA964778B (en) | 1997-12-08 |
| CO4700446A1 (es) | 1998-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP9802319A3 (en) | Pharmaceutical compositions for treatment of bone deficit conditions | |
| HUP9903489A3 (en) | Use of epinastine for the preparation of pharmaceutical compositions treating pain | |
| AP2001002270A0 (en) | Metalloproteinaise inhibitors pharmaceutical compositions containing them and their pharmaceeutical uses and methods and intermediates useful for their preparation | |
| HUP0000808A3 (en) | Pharmaceutical composition of fenofibrate and method for preparing same | |
| IL122118A (en) | Crystalline form I atorvastatin pharmaceutical compositions containing it and process for its preparation | |
| HUP0001607A3 (en) | Thienopyrimidine derivatives, pharmaceutical compositions containing them, process for their preparation and use of the compounds | |
| PL312064A1 (en) | Soft gelatinous form of pharmaceutical dose | |
| HUP9900849A3 (en) | Methods for preparing pharmaceutical compositions for minimizing bone loss effect of danazol | |
| IL118636A0 (en) | Oral pharmaceutical compositions of s(+)-etodolac | |
| HUP0003053A3 (en) | Crystalline forms of 33-epichloro-33-desoxyascomycin, process for their preparation and pharmaceutical compositions containing them | |
| EG22344A (en) | Process for preparing of novel pharmaceutical composition | |
| IL114673A0 (en) | Pharmaceutical compositions containing protein | |
| HUP9903684A3 (en) | Use of olanzapine for the preparation of pharmaceutical compositions treating depression | |
| HUP0000572A3 (en) | Pharmaceutical compositions containing nucleotide analogs and process for preparing them | |
| AP9600784A0 (en) | Oxathiolanes method for their preparation and pharmaceutical compositions containing them | |
| HUP9601680A3 (en) | Benzisothiazolyl-substituted aminomethyl-chromanes, pharmaceutical compositions containing the same, process for their preparation and use of the compounds | |
| HU9601261D0 (en) | Process for preparation of 2-fluor-pirimidine-derivatives | |
| EP0736323A3 (en) | Process for the production of micro-porous gel | |
| ZA966154B (en) | Aminophenylphosphonic acid compounds process for preparing them and pharmaceutical compositions containing them | |
| ZA963350B (en) | Cycloheaxane compounds process for their preparation and pharmaceutical compositions containing them | |
| HUP9903688A3 (en) | Use of olanzapine for the preparation of pharmaceutical compositions treating autism | |
| HUP9702477A3 (en) | New polymorphous form of doxazosin-mesylate (form iii), process for it's preparation and pharmaceutical compositions containing the same | |
| IL118573A (en) | Pharmaceutical compositions for minimizing bone loss | |
| GB9514224D0 (en) | Process for the preparation of prostheses for skeletal reconstruction | |
| HUP0001441A3 (en) | Process for the preparation of pharmaceutical compositions containing 4-aza-androst-1-ene derivatives |